Press release
PEGylated Protein Therapeutics Market Analysis Focusing on Top Key Players – Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. and more
PEGylated Protein Therapeutics Market
The factors that drive the growth of the global PEGylated protein therapeutics market are increase in prevalence of chronic diseases, advantages offered by PEGylation, and strong presence of pipe line drugs are. However, high cost related to drug development and launch of generics during the forecast period are expected to impede the market growth. In addition, high market potential in the untapped emerging economies and increase in adoption of PEGylated protein therapeutics are expected to provide many opportunities during the forecast period.
By product type, the colony stimulating factor segment accounted for nearly half share of the global occupational medicine market in 2017. Furthermore, the cancer segment is anticipated to grow at the highest rate of 7.4% during the forecast period.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/3726?utm_source=sy-Openpr
The report provides an extensive competitive analysis and profiles of the key market players such as
• Amgen Inc.
• AstraZeneca PLC
• Biogen Inc.
• F. Hoffmann-La Roche Ltd. (Genentech Inc.)
• Horizon Pharma plc.
• Leadiant Biosciences S.p.A.
• Merck & Co.
• Inc. (Schering-Plough Corporation)
• Pfizer Inc.
• Shire plc (Baxalta)
• UCB S.A.
PEGylation is a process of addition of active polyethylene glycol (PEG) to different forms of therapeutic proteins for chemical modification. These chemically modified therapeutic proteins are called PEGylated protein therapeutics. The chemical modification due to PEGylation results in various advantages, such as an extended half-life of a drug along with low toxicity and increased proteolytic protection, over the non-modified protein therapeutics. PEGylated protein therapeutics are used in multiple conditions such as cancer, hemophilia, rheumatoid arthritis, ankylosing spondylitis, Crohns disease, and others.
Buy Now (Data Pack Available with Discounted Price): @ https://www.alliedmarketresearch.com/checkout/729671?utm_source=sy-Openpr
Key Findings of the PEGylated Protein Therapeutics Market:
• North America occupied nearly two-thirds share of the global PEGylated protein therapeutics market in 2017
• The cancer segment is anticipated to grow with the highest CAGR throughout the forecast period.
• Europe is anticipated to occupy one-fifth market share of the global PEGylated protein therapeutics market by 2025.
• Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA.
North America was the leading revenue contributor to the global market in 2017, owing to FDA approval and launch of new drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR of 7.4% from 2018 to 2025, due to increase in affordability, surge in healthcare expenditure, and rise in awareness toward chronic disorders.
Access Full Summery @ https://www.alliedmarketresearch.com/PEGylated-proteins-market?utm_source=sy-Openpr
About Us:
Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.
Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PEGylated Protein Therapeutics Market Analysis Focusing on Top Key Players – Amgen Inc., AstraZeneca PLC, Biogen, Inc., F. Hoffmann-La Roche Ltd. and more here
News-ID: 1431328 • Views: …
More Releases from Allied Market Research
Converting Paper Market Poised for Remarkable Growth, to Surpass USD 545.9 Billi …
The global converting paper market was valued at $341.9 billion in 2023 and is projected to reach $545.9 billion by 2033, growing at a CAGR of 4.8% from 2024 to 2033. This growth is fueled by the increasing demand for customized paper products across various industries, including packaging, publishing, and e-commerce.
Get a Sample Copy of this Report: https://www.alliedmarketresearch.com/request-sample/A10550
Converting paper refers to the process of transforming raw paper…
![[2026] Trichlorosilane (TCS) Market Growing at a CAGR of 9.5% to 2033, Says AMR](https://cdn.open-pr.com/L/5/L526305139_g.jpg)
[2026] Trichlorosilane (TCS) Market Growing at a CAGR of 9.5% to 2033, Says AMR
Trichlorosilane (SiHCl3) is a silicon-based chemical compound with the molecular formula SiHCl3. It is a key intermediate in the production of silicon-based materials and is primarily used to manufacture polysilicon, which is the main component in solar cells and semiconductor devices. TCS is produced by the hydrochlorination of silicon tetrachloride (SiCl4) or by the reaction of silicon with hydrogen chloride. The global trichlorosilane market size was valued at $5.4 billion…
Insights into the Gallic Acid Market Growth, Global Industry Forecast, 2033
Gallic acid (C7H6O5), also known as 3,4,5-trihydroxybenzoic acid, is a naturally occurring phenolic acid found in many plants, fruits, and natural substances like tea, grapes, berries, and oak bark. It is a secondary plant metabolite that plays a key role in plant defense mechanisms. The global gallic acid market was valued at $81.0 million in 2023, and is projected to reach $137.5 million by 2033, growing at a CAGR of…
![[2026] Insights into Single Crystal Diamond Market Trend, Strategies, Growth Opportunities, 2033](https://cdn.open-pr.com/L/5/L525566526_g.jpg)
[2026] Insights into Single Crystal Diamond Market Trend, Strategies, Growth Opp …
A single crystal diamond is a diamond with a continuous and uninterrupted crystal lattice structure, free of grain boundaries or polycrystalline defects. Unlike polycrystalline diamonds, which have multiple small crystals fused together, single crystal diamonds have a perfect, uniform atomic arrangement. The global single crystal diamond market was valued at $1.5 billion in 2023, and is projected to reach $2.4 billion by 2033, growing at a CAGR of 4.7% from…
More Releases for PEG
Biopharma PEG Delivers Innovative PEG Solutions for Enhanced Drug Efficacy
Watertown, MA - October 24, 2024 - Biopharma PEG is excited to announce its extensive offerings of polyethylene glycol (PEG) products, including monofunctional, homobifunctional, heterobifunctional, and multi-arm PEGs, tailored for PEGylation in biopharmaceutical applications. With over 40 PEGylated drugs approved globally, the role of PEGylation in drug development is more critical than ever.
PEGylation provides numerous advantages, such as improved solubility, enhanced stability, and increased circulation time in the bloodstream. By…
Biopharma PEG Expands Multi-Arm PEG Product Line
Biopharma PEG, a leader in PEG derivatives, is excited to announce the expansion of its high-purity Multi-Arm PEG linker product line, catering to the evolving needs of the medical and bioorganic fields. These advanced PEG linkers are available in various functional groups and molecular weights ranging from 1k to 40k, offering unmatched versatility and performance for research and development in cutting-edge medical applications.
"Biopharma PEG is committed to delivering high-purity multi-arm…
Biopharma PEG Supplies PEG Products Used For Infectious Disease Vaccines
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. Advances in molecular technology have facilitated the development of other platforms, such as recombinant protein vaccines, nucleic acid vaccines, and viral vector vaccines, which have further diversified global vaccine development.
Recombinant protein vaccines accounted for the largest proportion of all pipeline in development, 22% (215), due…
Biopharma PEG Supplies PEG Products For Click Chemistry Reactions
What is "click chemistry"? "Click Chemistry", this is a literary name given to this kind of reaction by the Nobel Prize winner K.Burry Sharless, when the cards are put together, "click" (click). Simply put, it is to add two structures to two molecules respectively, and these two structures can be specifically combined to synthesize the required chemical molecules. One of the most famous click-chemistry reactions is the Cu-catalyzed azide-alkyne cycloaddition…
Biopharma PEG Develops PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ADC drug research has mushroomed and a large number of ADC drugs are in…
Biopharma PEG Provides Multi-arm PEG Derivatives Crosslinked Into Hydrogels
Polyethylene (ethylene glycol) is a hydrophilic polymer that can have a very high water content when cross-linked into a network. Polyethylene glycol (PEG) is a suitable material for biological applications because it does not normally elicit an immune response. Since the 1970s, PEG has been used to modify therapeutic proteins and peptides in order to increase their solubility, reduce their toxicity, and prolong their cyclic half-lives. In the late 1970s,…
